Second-line chemotherapy for refractory small cell neuroendocrine carcinoma of the esophagus that relapsed after complete remission with irinotecan plus cisplatin therapy: Case report and review of the literature
Authors:
- 30 October 2012
- journal article
- review article
- Published by Spandidos Publications in Oncology Letters
- Vol. 5 (1) , 117-122
Abstract
Small cell esophageal carcinoma is a type of small cell neuroendocrine carcinoma (SCNEC). SCNEC follows an aggressive clinical course and has a poor prognosis despite multidisciplinary therapies. A standard therapeutic strategy, including surgery, radiation and first-/second‑line chemotherapy, has not yet been established for SCNEC. We present a case of SCNEC of the esophagus. A 66-year-old male with SCNEC as extensive disease was treated with 60 mg/m2 cisplatin on day 1 plus 60 mg/m2 irinotecan on days 1, 8 and 15 every 4 weeks (IP) with successful complete remission. After the sixth course of IP, increasing pro-gastrin-releasing peptide (ProGRP) and nonspecific enolase (NSE) levels and intense fluorodeoxyglucose (FDG) avidity in a lymph node around the celiac artery (SUVmax, 8.3) indicated a refractory relapse of the disease. The patient was treated with three courses of amrubicin (AMR, 35 mg/m2) administered intravenously for 3 consecutive days every 3 weeks as a second‑line chemotherapy. The ProGRP and NSE levels returned to the normal range 1 month after the initiation of second-line chemotherapy. However, the ProGRP and NSE levels were elevated after the third course of AMR, and PET-CT revealed progressive disease with liver metastasis and extended lymph node metastasis. As the patient remained asymptomatic, paclitaxel (100 mg/m2) was started as third-line chemotherapy. Patients with SCNEC of the esophagus with extensive disease should be treated with aggressive chemotherapy rather than surgery or radiation monotherapy. In the present case, tumor markers such as ProGRP and NSE were predictive of relapse and PET-CT was used to detect relapse. Further research is required to identify and exploit promising agents for resistant SCNEC.Keywords
This publication has 32 references indexed in Scilit:
- Second-line chemotherapy for small-Cell Lung Cancer (SCLC)Cancer Treatment Reviews, 2011
- Radioembolization in the Treatment of Neuroendocrine Tumor Metastases to the LiverInternational Journal of Hepatology, 2011
- Staging of esophageal cancer: TNM and beyondEsophagus, 2010
- Small cell carcinomas in gastrointestinal tract: immunohistochemical and clinicopathological featuresJournal of Clinical Pathology, 2010
- The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statementVirchows Archiv, 2010
- Impact of 18F‐fluorodeoxyglucose positron emission tomography in the staging and treatment response assessment of extra‐pulmonary small‐cell cancerJournal of Medical Imaging and Radiation Oncology, 2010
- Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124Journal of Clinical Oncology, 2009
- Primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical features of 21 casesBMC Cancer, 2007
- The Pathology of Extrapulmonary Small Cell CarcinomaSeminars in Oncology, 2007
- Small Cell Carcinoma of the Esophagus with Reference to Alternating Multiagent Chemotherapy: Report of Two CasesSurgery Today, 2003